Recursion Pharmaceuticals stock hits 52-week low at $2.98

Recursion Pharmaceuticals Inc. stock reached a 52-week low, closing at $2.98. The biotechnology company, with a market capitalization of $1.58 billion, now trades 58% below its 52-week high of $7.18. This price marks a significant downturn for the company, which has seen its stock value decrease by 48.19% over the past year. This decline reflects challenges faced by the biotechnology firm, as it navigates the competitive landscape of drug discovery and development. The 52-week low highlights investor concerns and market pressures that have impacted Recursion Pharmaceuticals’ stock performance. According to InvestingPro analysis, the stock appears undervalued at current levels. The platform reveals that 5 analysts have recently revised their earnings upwards, among 8 additional ProTips available to subscribers. For deeper insights, investors can access the comprehensive Pro Research Report, available for RXRX and 1,400+ other US equities.

In other recent news, Recursion Pharmaceuticals reported impressive fourth-quarter 2025 earnings, surpassing both earnings and revenue forecasts. The company posted an earnings per share (EPS) of -$0.21, better than the anticipated -$0.30, with revenue hitting $35.54 million, exceeding expectations by 45%. In another development, Recursion announced that Vicki Goodman, M.D., will become Chief Medical Officer effective April 6, 2026, succeeding David Mauro, M.D., Ph.D. Goodman brings extensive experience in oncology drug development from her previous roles at Mural Oncology and Exelixis. Additionally, BofA Securities recently adjusted its price target for Recursion Pharmaceuticals to $6.00 from $7.00, maintaining a Neutral rating. The firm emphasized the need for the company to achieve repeatable clinical successes to demonstrate the efficacy of its AI-driven platform. These developments highlight the ongoing evolution within Recursion Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.